WHO and Switzerland launch BioHub for pathogen storage and analysis
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
List view / Grid view
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
Our comprehensive portfolio suite is designed to optimize your productivity to get safe and efficacious vaccines and therapeutics to market faster.
Researchers have developed a technique to synthetically produce DNA oligonucleotides that avoids the degradation of phosphoramidites.
A team has characterised a key part of the peptide synthesis process, showing that only the main building block needs to be changed for re-engineering.
The development of a Parkinson’s disease model, using hiPSC-derived neural cells, to assess alpha-synuclein pre-formed fibril-induced toxicity.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
11 May 2021 | By PerkinElmer
Get the Big Picture and listen to Pharma thought leaders how they view CETSA® and its impact on their Drug Discovery.
In this short video we show an example of a 3D airway organoid model along with some interesting ways to get the most out of this type of assay.
Researchers have used cryo-EM to show that a new nanobody cocktail can bind to the S protein of SARS-CoV-2, neutralising the coronavirus.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
22 April 2021 | By IDBS
Register today for our on-demand upcoming webinar and discover more on about Polar High-Throughput Process Development (HTPD).
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.